Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?

This article was originally published in The Gray Sheet

Executive Summary

For a select few devices per year, FDA says it will speed up pre-market development times by intensifying staff efforts, with a particular focus on very early-stage, frequent interactions with product sponsors.

You may also be interested in...

Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill

CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.

Planned PMA Pathway Modeled On Existing Accelerated Programs

CDRH’s plans for a specialized pathway for high-risk PMA devices that address unmet medical needs will be modeled on the drug center’s recently established breakthrough therapy pathway, and also the device center’s Innovation Pathway.

Companion Diagnostics For Breakthrough Drugs Also Getting Swift Attention, FDA Says

Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough therapies from coming to market.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts